Literature DB >> 35655624

A Case of Delayed COVID-19-Related Macrophage Activation Syndrome.

Abdelnassir Abdelgabar1, Mohammed Elsayed1.   

Abstract

Although coronavirus disease 2019 (COVID-19) is primarily a respiratory illness, clinical experiences have shown that almost no system is exempted. The severity of the disease can also range from mild presentation with complaints such as headache, aches and pains, taste and sense of smell disturbances to a more severe presentation with acute respiratory distress syndrome (ARDS) that necessitate admission to intensive care units. In such severe presentation, hypercytokinemia, typically found in cytokine storm syndrome (CSS), particularly macrophage activation syndrome (MAS) is often present. CSS can result from diverse, heterogeneous conditions of different clinical phenotypes, such as infections, hematological, rheumatological or iatrogenic conditions leading to systemic hyperinflammation. Some clinical and laboratory findings may give clues to such a highly lethal syndrome and allow early diagnosis and introduction of effective therapy. In this case we describe a COVID-19 pneumonia patient who was discharged home following improvement in his respiratory symptoms to present few days later with a fatal form of CSS, presenting with ARDS, fulminant hepatic failure and coagulopathy. Copyright 2022, Abdelgabar et al.

Entities:  

Keywords:  COVID-19; Cytokines storm syndrome; Hyperinflammatory syndrome; Macrophage activation syndrome

Year:  2022        PMID: 35655624      PMCID: PMC9119367          DOI: 10.14740/jmc3903

Source DB:  PubMed          Journal:  J Med Cases        ISSN: 1923-4155


  14 in total

1.  High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation.

Authors:  Olivier Lambotte; Patrice Cacoub; Nathalie Costedoat; Gisele Le Moel; Zahir Amoura; Jean-Charles Piette
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

Review 2.  Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.

Authors:  Edward M Behrens; Gary A Koretzky
Journal:  Arthritis Rheumatol       Date:  2017-06       Impact factor: 10.995

3.  Cytokine release syndrome in severe COVID-19.

Authors:  John B Moore; Carl H June
Journal:  Science       Date:  2020-04-17       Impact factor: 47.728

4.  The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19.

Authors:  Giuseppe G Loscocco; Danilo Malandrino; Simone Barchiesi; Andrea Berni; Loredana Poggesi; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Int J Lab Hematol       Date:  2020-08-10       Impact factor: 2.877

5.  IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.

Authors:  Rudragouda Channappanavar; Anthony R Fehr; Jian Zheng; Christine Wohlford-Lenane; Juan E Abrahante; Matthias Mack; Ramakrishna Sompallae; Paul B McCray; David K Meyerholz; Stanley Perlman
Journal:  J Clin Invest       Date:  2019-07-29       Impact factor: 14.808

Review 6.  [An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2020-02-10

7.  Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment.

Authors:  Susanna K P Lau; Candy C Y Lau; Kwok-Hung Chan; Clara P Y Li; Honglin Chen; Dong-Yan Jin; Jasper F W Chan; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  J Gen Virol       Date:  2013-09-28       Impact factor: 3.891

8.  Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.

Authors:  Brandon J Webb; Ithan D Peltan; Paul Jensen; Daanish Hoda; Bradley Hunter; Aaron Silver; Nathan Starr; Whitney Buckel; Nancy Grisel; Erika Hummel; Gregory Snow; Dave Morris; Eddie Stenehjem; Rajendu Srivastava; Samuel M Brown
Journal:  Lancet Rheumatol       Date:  2020-09-29

Review 9.  Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options.

Authors:  Ellen Brisse; Patrick Matthys; Carine H Wouters
Journal:  Br J Haematol       Date:  2016-06-12       Impact factor: 6.998

Review 10.  Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.

Authors:  Miriam Merad; Jerome C Martin
Journal:  Nat Rev Immunol       Date:  2020-05-06       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.